1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PIQUR Therapeutics AG - Product Pipeline Review - 2015

PIQUR Therapeutics AG - Product Pipeline Review - 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 28 pages

PIQUR Therapeutics AG - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘PIQUR Therapeutics AG - Product Pipeline Review - 2015’, provides an overview of the PIQUR Therapeutics AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PIQUR Therapeutics AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of PIQUR Therapeutics AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of PIQUR Therapeutics AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the PIQUR Therapeutics AG’s pipeline products

Reasons to buy

- Evaluate PIQUR Therapeutics AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of PIQUR Therapeutics AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the PIQUR Therapeutics AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of PIQUR Therapeutics AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of PIQUR Therapeutics AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of PIQUR Therapeutics AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

PIQUR Therapeutics AG - Product Pipeline Review - 2015
Table of Contents
PIQUR Therapeutics AG Snapshot 5
PIQUR Therapeutics AG Overview 5
Key Information 5
Key Facts 5
PIQUR Therapeutics AG - Research and Development Overview 6
Key Therapeutic Areas 6
PIQUR Therapeutics AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
PIQUR Therapeutics AG - Pipeline Products Glance 10
PIQUR Therapeutics AG - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
PIQUR Therapeutics AG - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
PIQUR Therapeutics AG - Drug Profiles 13
PQR-309 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
PQR-401 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
PQR-5XX 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
PQR-6XX 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
PQR-311 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
PQR-316 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Small Molecules for Undisclosed Indication 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
PIQUR Therapeutics AG - Pipeline Analysis 20
PIQUR Therapeutics AG - Pipeline Products by Target 20
PIQUR Therapeutics AG - Pipeline Products by Route of Administration 21
PIQUR Therapeutics AG - Pipeline Products by Molecule Type 22
PIQUR Therapeutics AG - Pipeline Products by Mechanism of Action 23
PIQUR Therapeutics AG - Recent Pipeline Updates 24
PIQUR Therapeutics AG - Dormant Projects 25
PIQUR Therapeutics AG - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 27
Disclaimer 28

List of Tables
PIQUR Therapeutics AG, Key Information 5
PIQUR Therapeutics AG, Key Facts 5
PIQUR Therapeutics AG - Pipeline by Indication, 2015 7
PIQUR Therapeutics AG - Pipeline by Stage of Development, 2015 8
PIQUR Therapeutics AG - Monotherapy Products in Pipeline, 2015 9
PIQUR Therapeutics AG - Phase I, 2015 10
PIQUR Therapeutics AG - Preclinical, 2015 11
PIQUR Therapeutics AG - Discovery, 2015 12
PIQUR Therapeutics AG - Pipeline by Target, 2015 20
PIQUR Therapeutics AG - Pipeline by Route of Administration, 2015 21
PIQUR Therapeutics AG - Pipeline by Molecule Type, 2015 22
PIQUR Therapeutics AG - Pipeline Products by Mechanism of Action, 2015 23
PIQUR Therapeutics AG - Recent Pipeline Updates, 2015 24
PIQUR Therapeutics AG - Dormant Developmental Projects,2015 25

List of Figures
PIQUR Therapeutics AG - Pipeline by Top 10 Indication, 2015 7
PIQUR Therapeutics AG - Pipeline by Stage of Development, 2015 8
PIQUR Therapeutics AG - Monotherapy Products in Pipeline, 2015 9
PIQUR Therapeutics AG - Pipeline by Top 10 Target, 2015 20
PIQUR Therapeutics AG - Pipeline by Top 10 Molecule Type, 2015 22
PIQUR Therapeutics AG - Pipeline Products by Top 10 Mechanism of Action, 2015 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.